2.0
May 1, 2013
Former employee, more than 3 years
Sunnyvale, CA
Recommend
CEO approval
Business Outlook
Pros
MolDev is a nice little biotech still suffering growing pains from its early start up days.
Cons
Since MolDev sold itself to MDS in 2006, then later Danaher, it has struggled for clear direction and market positioning